Filter Results

Clinical Studies

Open

Closed for Enrollment

  • Inherited Breast Cancer Study Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The purpose of this study is to improve the interpretation of mutations in breast cancer predisposition genes. This will be accomplished by recruiting members of families found to carry deleterious (mainly protein truncating) mutations and evaluating co-segregation of the mutations with cancer within families.
  • Prospective Registry of Multiplex Testing (PROMPT) Phase II (PROMPT) Rochester, Minn.

    The purpose of this study is to collect patient and family DNA and disease data to learn more about how changes in certain genes may be linked to cancer. Some people with cancer may have aquired their disease because they inherited an abnormal (mutated) gene. The researchers of this study want to better understand the risks that are linked to genetic changes in these less well-studied genes. By understanding these risks, it is believed that doctors will be able to give better advice to families with mutations in these genes.
  • The Mayo Clinic Breast Disease Survivors Study Rochester, Minn. This study will recruit breast cancer patients and survivors to take part in an ongoing study of the issues and concerns surrounding breast cancer survivorship. We will recruit both newly diagnosed patients as well as patients diagnosed within the past 5 years. Those who consent to the study will be asked to provide a series of questionnaires and blood samples over time. These data/samples will create a repository that will enable us to address many specific hypotheses both now and in the future. As part of the study DNA samples will be genotyped for common genetic variants in an effort to identify common genetic breast cancer risk factors.
  • The Predicting Risk after Screening Mammogram (PRISM) Study (PRISM) Rochester, Minn.

    The purpose of this study is the creation of a long-term prospective observational study of women undergoing screening mammography at Mayo Clinic. The cohort will be used to evaluate risk models for breast cancer incorporating epidemiological risk factors, genetic risk factors, breast density measures, imaging data, results from diagnostic tissue biopsies, and liquid biopsy assays. The cohort will also be useful for clinical validation and assessment of clinical utility of predictive and prognostic biomarkers for breast cancer.
.